Cargando…

Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B

Nucleos(t)ide analogues (NAs) are widely used for antiviral therapy in patients with chronic hepatitis B (CHB), but real-world data on treatment patterns and long-term clinical outcomes are not always available. Using data from electronic medical records between January 2011 and December 2016 in Sha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Y., Zhang, Y., Xu, Y., Shu, M., Bonroy, K., Qiu, H., Cai, W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2019
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518842/ https://www.ncbi.nlm.nih.gov/pubmed/31364558 http://dx.doi.org/10.1017/S0950268819000815

Ejemplares similares

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Comparison of the Antiviral Effects of Different Nucleos(t)ide Analogues in Chinese Patients with Chronic Hepatitis B: A Head-to-Head Study
por: Yu, Shu, et al.
Publicado: (2014)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
por: de Fraga, Raquel Scherer, et al.
Publicado: (2020)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Lim, Joseph K, et al.
Publicado: (2020)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis
por: Chen, Zhe, et al.
Publicado: (2015)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
por: Hsu, Yao-Chun, et al.
Publicado: (2023)

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
por: He, Dengming, et al.
Publicado: (2013)

Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
por: Adali, Gupse, et al.
Publicado: (2021)

Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B
por: Qi, Xun, et al.
Publicado: (2015)

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis
por: Ford, Nathan, et al.
Publicado: (2018)

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
por: Huang, Mingxing, et al.
Publicado: (2017)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
por: Zhou, Jialing, et al.
Publicado: (2016)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
por: Hall, Samuel, et al.
Publicado: (2020)

Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B
por: Madeddu, Giordano, et al.
Publicado: (2020)

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
por: Broquetas, Teresa, et al.
Publicado: (2022)

48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
por: Xu, Wen-xiong, et al.
Publicado: (2018)

Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues
por: Qian, Fuchu, et al.
Publicado: (2020)

Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
por: Wang, Xinhui, et al.
Publicado: (2020)

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey
por: Chen, Jing Wen, et al.
Publicado: (2022)

Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
por: Guo, Yafei, et al.
Publicado: (2019)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
por: Ogawa, Eiichi, et al.
Publicado: (2022)

Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues
por: Goel, Varun, et al.
Publicado: (2013)

Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
por: Maier, Melanie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q92vcilt93f8o5800nnlklg07s